Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study
Authors' conclusion
Semaglutide demonstrated notable improvement in obesity, metabolic, and cardiovascular disease risk outcomes in a clinical setting.
Study context
- Population
- Patients with body-mass index (BMI) ≥ 27 kg/m² prescribed weekly subcutaneous semaglutide; excluded bariatric surgery, other anti-obesity medications, active malignancy or pregnancy; 73% female, 93% White, mean age 48.8 [12.4] years, BMI 40.9 [9.6] kg/m²304 analysed
- Participants
- 1,023 patients
- Outcome
- Total body weight loss percentage (TBWL%)
- Follow-up
- 12 months
Methodological detailsmulticentre, single-group
- Multicentre
- Single-group
Main finding
As reported in the abstract
TBWL%
- TBWL at 12 months, all patients (n = 304 analysed)
- 13.4 (8.0)%
- P vs baseline
- p < 0.001 from baseline
Observational data: associations, not effects.
Secondary outcomes
| Outcome | Values |
|---|---|
| Proportion achieving TBWL thresholds · 12 months | Semaglutide 81% · ≥5% TBWL 81% · ≥10% TBWL 64% · ≥15% TBWL 41% · ≥20% TBWL 22% |
TBWL by T2DM status on higher semaglutide doses · 12 months
- TBWL from baseline in subgroups by T2DM status
- P < 0.001
Metabolic, lipid, blood pressure, liver function and CVD risk outcomes · 12 months
- Significant improvements in metabolic, lipid profile, blood pressure, liver function tests and CVD risk outcomes
Original publication
Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study. Int J Obes (Lond). Published 1 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →